Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Accumulated Expenses (2018 - 2023)

Endonovo Therapeutics has reported Accumulated Expenses over the past 7 years, most recently at $630568.0 for Q3 2023.

  • Quarterly results put Accumulated Expenses at $630568.0 for Q3 2023, up 180.25% from a year ago — trailing twelve months through Sep 2023 was $630568.0 (up 180.25% YoY), and the annual figure for FY2022 was $523818.0, down 79.28%.
  • Accumulated Expenses for Q3 2023 was $630568.0 at Endonovo Therapeutics, down from $4.1 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for ENDV hit a ceiling of $4.6 million in Q1 2023 and a floor of $75346.0 in Q1 2021.
  • Median Accumulated Expenses over the past 5 years was $1.9 million (2020), compared with a mean of $1.9 million.
  • Biggest five-year swings in Accumulated Expenses: crashed 96.75% in 2021 and later skyrocketed 4502.13% in 2022.
  • Endonovo Therapeutics' Accumulated Expenses stood at $2.4 million in 2019, then dropped by 21.68% to $1.9 million in 2020, then soared by 32.79% to $2.5 million in 2021, then tumbled by 79.28% to $523818.0 in 2022, then grew by 20.38% to $630568.0 in 2023.
  • The last three reported values for Accumulated Expenses were $630568.0 (Q3 2023), $4.1 million (Q2 2023), and $4.6 million (Q1 2023) per Business Quant data.